Rlip depletion prevents spontaneous neoplasia in TP53 null mice

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• TP53 (p53) is a critical tumor suppressor frequently inactivated in cancers.
• p53 knockout mice develop spontaneous malignancies, primarily T-cell lymphoma.
• RALBP1 (RLIP76, Rlip) is involved in stress response and endocytosis, and its deficiency confers resistance to carcinogenesis.

Purpose of the Study:

• To investigate the therapeutic potential of RLIP deficiency in suppressing spontaneous malignancy in p53-deficient mice.
• To explore the impact of RLIP inhibition on methylomic and transcriptomic alterations in cancer development.
• To examine the role of RLIP in the p53-mediated tumor suppression pathway.

Main Methods:

• Weekly administration of a RLIP-specific antisense oligonucleotide (R508) to p53 knockout mice.
• Induction of carcinogenesis using benzo(a)pyrene in p53 knockout mice.
• Analysis of methylomic and transcriptomic profiles, and cross-breeding experiments.

Main Results:

• Partial RLIP deficiency strongly inhibited spontaneous and benzo(a)pyrene-induced carcinogenesis in p53 knockout mice.
• R508 treatment prevented widespread methylomic and transcriptomic abnormalities associated with inflammation in tumors.
• Hemizygous RLIP deficiency also reduced spontaneous malignancy in p53 heterozygous mice.
• Anti-RLIP antibodies inhibited cancer cell growth and promoted apoptosis.

Conclusions:

• RLIP deficiency is a highly effective strategy for suppressing spontaneous malignancy in p53-deficient models.
• Targeting RLIP offers a novel paradigm for tumor suppression, potentially applicable to hereditary cancer syndromes like Li-Fraumeni.
• The findings elucidate mechanisms of p53 tumor suppression and highlight RLIP as a therapeutic target.